2α-Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast Differentiation of Dedifferentiated Fat Cells
<p>Chemical structures of 2α-substituted vitamin D derivatives. (<b>A</b>) 2α-Hydroxyalkoxylated derivatives, O2C2, O2C3, and O2C4. (<b>B</b>) 2α-Hydroxyalkylated derivatives, O1C1, O1C2, O1C3, and O1C4. The details about the compounds were reported previously [<a href="#B10-biomolecules-14-00706" class="html-bibr">10</a>,<a href="#B11-biomolecules-14-00706" class="html-bibr">11</a>].</p> "> Figure 2
<p>Effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> and vitamin D derivatives on VDR transactivation activity and interactions of VDR with RXR and SRC-1. The effects of O2C2, O2C3, and O2C4 on VDR transactivation (<b>A</b>), VDR–RXR interaction (<b>B</b>), and VDR–SRC1 interaction (<b>C</b>), and those of O1C1, O1C2, O1C3, and O1C4 on VDR transactivation (<b>D</b>), VDR–RXR interaction (<b>E</b>), and VDR–SRC1 interaction were compared to those of 1,25(OH)<sub>2</sub>D<sub>3</sub>. HEK293 cells were transfected with pCMX−VDR and TK-Spp × 3-LUC reporter plasmid, CMX-VP16-VDR, CMX-GAL4-RXRα, and MH100(UAS) × 4-tk-LUC reporter plasmid, and CMX-VP16-VDR, CMX-GAL4-SRC-1, and MH100(UAS) × 4-tk-LUC reporter plasmid for VDR transactivation activity (<b>A</b>,<b>D</b>), interaction of VDR with RXRα (<b>B</b>,<b>E</b>), and that with SRC-1 (<b>C</b>,<b>F</b>), respectively. Cells were treated with a range of concentrations of each compound (0–10 nM). Luciferase activity values are expressed relative to those of 10 nM 1,25(OH)<sub>2</sub>D<sub>3</sub>, which are set at 100%.</p> "> Figure 3
<p>Effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> and vitamin D derivatives on mRNA expression of the VDR target genes in human cells. The effects of O2C2, O2C3, and O2C4 (<b>A</b>,<b>C</b>,<b>E</b>,<b>G</b>) and those of O1C1, O1C2, O1C3, and O1C4 (<b>B</b>,<b>D</b>,<b>F</b>,<b>H</b>) were compared to those of 1,25(OH)<sub>2</sub>D<sub>3</sub>. Human kidney-derived HEK293 cells (<b>A</b>,<b>B</b>), intestinal mucosa-derived CaCO<sub>2</sub> cells (<b>C</b>,<b>D</b>), and osteoblast-derived MG63 cells (<b>E</b>–<b>H</b>) were treated with a vehicle (ethanol) control (CNT), 1,25(OH)<sub>2</sub>D<sub>3</sub> or vitamin D derivative (10 nM) for 24 h, and mRNA expression of <span class="html-italic">CYP24A1</span> (<b>A</b>–<b>F</b>) and <span class="html-italic">BGLAP</span> (<b>G</b>,<b>H</b>) was determined with reverse transcription and quantitative real-time PCR analysis. mRNA levels were normalized to the level of 18S rRNA and expressed relative to those of cells treated with 1,25(OH)<sub>2</sub>D<sub>3</sub>, which are set at 100%. One-way ANOVA followed by Dunnett’s multiple comparisons. ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001 versus CNT; # <span class="html-italic">p</span> < 0.05, ## <span class="html-italic">p</span> < 0.01, ### <span class="html-italic">p</span> < 0.001 versus 1,25(OH)<sub>2</sub>D<sub>3</sub>.</p> "> Figure 4
<p>Effects of vitamin D derivatives on <span class="html-italic">Cyp24a1</span> expression in the kidney and small intestine, and plasma calcium and phosphorus levels in mice. (<b>A</b>) Effects of O2C2 and O2C3 on <span class="html-italic">Cyp24a1</span> mRNA expression in the kidney, duodenum, jejunum, and ileum were compared to those of 1,25(OH)<sub>2</sub>D<sub>3</sub>. (<b>B</b>) Effects of O2C2 and O2C3 on plasma calcium and phosphorus levels were compared to those of 1,25(OH)<sub>2</sub>D<sub>3</sub>. Effects of O1C3 on <span class="html-italic">Cyp24a1</span> mRNA expression (<b>C</b>) and plasma calcium and phosphorus levels (<b>D</b>) were also examined. Mice were administered vehicle (ethanol) control (CNT), 12.5 nmol/kg 1,25(OH)<sub>2</sub>D<sub>3</sub>, O2C2, O2C3, or O1C3 via intraperitoneal injection, and blood and tissue samples were collected 6 h after injection. mRNA levels were normalized to the level of <span class="html-italic">GAPDH</span> mRNA and expressed relative to those of 1,25(OH)<sub>2</sub>D<sub>3</sub>-treated mice, which are set at 100%. Data are presented as means ± S.D. One-way ANOVA followed by Dunnett’s multiple comparisons. * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001 versus CNT; # <span class="html-italic">p</span> < 0.05; ## <span class="html-italic">p</span> < 0.01, ### <span class="html-italic">p</span> < 0.001 versus 1,25(OH)<sub>2</sub>D<sub>3</sub>.</p> "> Figure 5
<p>Effects of vitamin D derivatives on the expression of the VDR target gene <span class="html-italic">CYP24A1</span> (<b>A</b>), the osteoblast marker genes <span class="html-italic">SPP1</span> (<b>B</b>), <span class="html-italic">BGLAP</span> (<b>C</b>), and <span class="html-italic">RUNX2</span> (<b>D</b>), and the adipocyte marker gene <span class="html-italic">PPARG</span> (<b>E</b>) in human DFAT cells. Cells were treated with vehicle (ethanol) control (CNT), 10 nM 1,25(OH)<sub>2</sub>D<sub>3</sub>, or vitamin D derivative for 24 h, and the expression of each gene was determined via reverse transcription and quantitative real-time PCR analysis. mRNA levels were normalized to the level of 18S rRNA and expressed relative to those of cells treated with 1,25(OH)<sub>2</sub>D<sub>3</sub>, which are set at 100%. One-way ANOVA followed by Dunnett’s multiple comparisons. * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001 versus CNT; ## <span class="html-italic">p</span> < 0.01, ### <span class="html-italic">p</span> < 0.001 versus 1,25(OH)<sub>2</sub>D<sub>3</sub>.</p> "> Figure 6
<p>Effects of vitamin D derivatives on osteoblast differentiation in human DFAT cells. Cells were treated without or with OM in the presence of vehicle (ethanol) control (CNT), 10 nM 1,25(OH)<sub>2</sub>D<sub>3</sub>, or vitamin D derivative. OM plus test compound was changed on day 4 (<b>A</b>) or left unchanged (<b>B</b>). ALP activity was evaluated on day 7. ALP activity was determined in cell lysates and normalized to protein content and expressed relative to those of cells treated with OM plus 1,25(OH)<sub>2</sub>D<sub>3</sub>, which are set at 100%. One-way ANOVA followed by Dunnett’s multiple comparisons. * <span class="html-italic">p</span> < 0.05, ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001 versus OM + CNT (<span class="html-italic">p</span> = 0.07, OM + 1,25(OH)<sub>2</sub>D<sub>3</sub> versus OM + CNT in (<b>A</b>) right panel); # <span class="html-italic">p</span> < 0.05, ## <span class="html-italic">p</span> < 0.01, ### <span class="html-italic">p</span> < 0.001 versus OM + 1,25(OH)<sub>2</sub>D<sub>3</sub>.</p> "> Figure 7
<p>Stability of 1,25(OH)<sub>2</sub>D<sub>3</sub>, O2C3, and O1C3 in human DFAT cells. Cells were treated with OM plus 1 μM 1,25(OH)<sub>2</sub>D3, O2C3, or O1C3 for 3 days (“with cells”). Each compound was also incubated with OM in the absence of cells for 3 days (“without cells”). Compounds were extracted from medium +/− cells and analyzed with HPLC. Peak areas for compounds in HPLC were expressed relative to those without cells, which are set at 100%. Unpaired two-group Student’s <span class="html-italic">t</span> test: * <span class="html-italic">p</span> < 0.05, *** <span class="html-italic">p</span> < 0.001.</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Vitamin D Derivatives
2.2. Cell Cultures
2.3. Luciferase Reporter Assays
2.4. Mouse Experiments
2.5. Human DFAT Cell Isolation and Culture
2.6. Reverse Transcription and Quantitative Real-Time PCR Analysis
2.7. Differentiation Assay
2.8. High-Performance Liquid Chromatography
2.9. Statistical Analysis
3. Results
3.1. Effects of Vitamin D Derivatives on VDR Transactivation Activity and Interaction of VDR with RXR and SRC-1
3.2. Effects of Vitamin D Derivatives on Tissue Cyp24a1 Expression and Plasma Calcium and Phosphorus Levels in Mice
3.3. Effects of Vitamin D Derivatives on Osteoblast Differentiation in Human DFAT Cells
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Rosen, C.J.; Adams, J.S.; Bikle, D.D.; Black, D.M.; Demay, M.B.; Manson, J.E.; Murad, M.H.; Kovacs, C.S. The nonskeletal effects of vitamin D: An endocrine society scientific statement. Endocr. Rev. 2012, 33, 456–492. [Google Scholar] [CrossRef]
- Haussler, M.R.; Whitfield, G.K.; Kaneko, I.; Haussler, C.A.; Hsieh, D.; Hsieh, J.C.; Jurutka, P.W. Molecular mechanisms of vitamin D action. Calcif. Tissue Int. 2013, 92, 77–98. [Google Scholar] [CrossRef]
- Xu, Y.; Hashizume, T.; Shuhart, M.C.; Davis, C.L.; Nelson, W.L.; Sakaki, T.; Kalhorn, T.F.; Watkins, P.B.; Schuetz, E.G.; Thummel, K.E. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1α,25-dihydroxyvitamin D3: Implications for drug-induced osteomalacia. Mol. Pharmacol. 2006, 69, 56–65. [Google Scholar] [CrossRef]
- Orimo, H.; Shiraki, M.; Hayashi, Y.; Hoshino, T.; Onaya, T.; Miyazaki, S.; Kurosawa, H.; Nakamura, T.; Ogawa, N. Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 1994, 54, 370–376. [Google Scholar] [CrossRef]
- Matsumoto, T.; Yamamoto, K.; Takeuchi, T.; Tanaka, Y.; Tanaka, S.; Nakano, T.; Ito, M.; Tomomitsu, T.; Hirakawa, A.; Soen, S. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). J. Bone Miner. Metab. 2020, 38, 522–532. [Google Scholar] [CrossRef]
- Chen, J.; Tang, Z.; Slominski, A.T.; Li, W.; Zmijewski, M.A.; Liu, Y.; Chen, J. Vitamin D and its analogs as anticancer and anti-inflammatory agents. Eur. J. Med. Chem. 2020, 207, 112738. [Google Scholar] [CrossRef]
- Pike, J.W.; Meyer, M.B. New approaches to assess mechanisms of action of selective vitamin D analogues. Int. J. Mol. Sci. 2021, 22, 12352. [Google Scholar] [CrossRef]
- Kittaka, A. Creation of potent vitamin D receptor agonists and antagonists with 2α-(ω-hydroxyalkylation) concept to the seco-steroid skeleton. Chimia 2018, 72, 859–865. [Google Scholar] [CrossRef]
- Maestro, M.A.; Molnar, F.; Carlberg, C. Vitamin D and its synthetic analogs. J. Med. Chem. 2019, 62, 6854–6875. [Google Scholar] [CrossRef]
- Saito, N.; Suhara, Y.; Kurihara, M.; Fujishima, T.; Honzawa, S.; Takayanagi, H.; Kozono, T.; Matsumoto, M.; Ohmori, M.; Miyata, N.; et al. Design and efficient synthesis of 2α-(ω-hydroxyalkoxy)-1α,25-dihydroxyvitamin D3 analogues, including 2-epi-ed-71 and their 20-epimers with HL-60 cell differentiation activity. J. Org. Chem. 2004, 69, 7463–7471. [Google Scholar] [CrossRef]
- Suhara, Y.; Nihei, K.I.; Kurihara, M.; Kittaka, A.; Yamaguchi, K.; Fujishima, T.; Konno, K.; Miyata, N.; Takayama, H. Efficient and versatile synthesis of novel 2α-substituted 1α,25-dihydroxyvitamin D3 analogues and their docking to vitamin D receptors. J. Org. Chem. 2001, 66, 8760–8771. [Google Scholar] [CrossRef]
- Takahashi, E.; Nakagawa, K.; Suhara, Y.; Kittaka, A.; Nihei, K.; Konno, K.; Takayama, H.; Ozono, K.; Okano, T. Biological activities of 2α-substituted analogues of 1α,25-dihydroxyvitamin D3 in transcriptional regulation and human promyelocytic leukemia (HL-60) cell proliferation and differentiation. Biol. Pharm. Bull. 2006, 29, 2246–2250. [Google Scholar] [CrossRef]
- Suhara, Y.; Nihei, K.I.; Tanigawa, H.; Fujishima, T.; Konno, K.; Nakagawa, K.; Okano, T.; Takayama, H. Syntheses and biological evaluation of novel 2α-substituted 1α,25-dihydroxyvitamin D3 analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1129–1132. [Google Scholar] [CrossRef]
- Yasuda, K.; Ikushiro, S.; Kamakura, M.; Takano, M.; Saito, N.; Kittaka, A.; Chen, T.C.; Ohta, M.; Sakaki, T. Human cytochrome P450-dependent differential metabolism among three 2α-substituted-1α,25-dihydroxyvitamin D3 analogs. J. Steroid Biochem. Mol. Biol. 2013, 133, 84–92. [Google Scholar] [CrossRef]
- Yagi, K.; Kondo, D.; Okazaki, Y.; Kano, K. A novel preadipocyte cell line established from mouse adult mature adipocytes. Biochem. Biophys. Res. Commun. 2004, 321, 967–974. [Google Scholar] [CrossRef]
- Matsumoto, T.; Kano, K.; Kondo, D.; Fukuda, N.; Iribe, Y.; Tanaka, N.; Matsubara, Y.; Sakuma, T.; Satomi, A.; Otaki, M.; et al. Mature adipocyte-derived dedifferentiated fat cells exhibit multilineage potential. J. Cell. Physiol. 2008, 215, 210–222. [Google Scholar] [CrossRef]
- De Kok, I.J.; Hicok, K.C.; Padilla, R.J.; Young, R.G.; Cooper, L.F. Effect of vitamin D pretreatment of human mesenchymal stem cells on ectopic bone formation. J. Oral Implantol. 2006, 32, 103–109. [Google Scholar] [CrossRef]
- Fuggle, N.R.; Cooper, C.; Oreffo, R.O.C.; Price, A.J.; Kaux, J.F.; Maheu, E.; Cutolo, M.; Honvo, G.; Conaghan, P.G.; Berenbaum, F.; et al. Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clin. Exp. Res. 2020, 32, 547–560. [Google Scholar] [CrossRef]
- Zhou, Y.-S.; Liu, Y.-S.; Tan, J.-G. Is 1, 25-dihydroxyvitamin D3 an ideal substitute for dexamethasone for inducing osteogenic differentiation of human adipose tissue-derived stromal cellsin vitro? Chin. Med. J. 2006, 119, 1278–1286. [Google Scholar] [CrossRef]
- Ha, N.N.; Huynh, T.K.T.; Phan, N.U.P.; Nguyen, T.H.; Vong, L.B.; Trinh, N.T. Synergistic effect of metformin and vitamin D3 on osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells under high D-glucose conditions. Regen. Ther. 2024, 25, 147–156. [Google Scholar] [CrossRef]
- Jing, W.; Xiong, Z.; Cai, X.; Huang, Y.; Li, X.; Yang, X.; Liu, L.; Tang, W.; Lin, Y.; Tian, W. Effects of gamma-secretase inhibition on the proliferation and vitamin D3 induced osteogenesis in adipose derived stem cells. Biochem. Biophys. Res. Commun. 2010, 392, 442–447. [Google Scholar] [CrossRef]
- Maekawa, K.; Ishizawa, M.; Ikawa, T.; Sajiki, H.; Matsumoto, T.; Tokiwa, H.; Makishima, M.; Yamada, S. Syntheses of 25-adamantyl-25-alkyl-2-methylidene-1α,25-dihydroxyvitamin D3 derivatives with structure-function studies of antagonistic and agonistic active vitamin D analogs. Biomolecules 2023, 13, 1082. [Google Scholar] [CrossRef]
- Ishizawa, M.; Matsunawa, M.; Adachi, R.; Uno, S.; Ikeda, K.; Masuno, H.; Shimizu, M.; Iwasaki, K.; Yamada, S.; Makishima, M. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J. Lipid Res. 2008, 49, 763–772. [Google Scholar] [CrossRef]
- Nakahashi, O.; Yamamoto, H.; Tanaka, S.; Kozai, M.; Takei, Y.; Masuda, M.; Kaneko, I.; Taketani, Y.; Iwano, M.; Miyamoto, K.; et al. Short-term dietary phosphate restriction up-regulates ileal fibroblast growth factor 15 gene expression in mice. J. Clin. Biochem. Nutr. 2014, 54, 102–108. [Google Scholar] [CrossRef]
- Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8, 315–317. [Google Scholar] [CrossRef]
- Inaba, Y.; Yamamoto, K.; Yoshimoto, N.; Matsunawa, M.; Uno, S.; Yamada, S.; Makishima, M. Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin d receptor modulators. Mol. Pharmacol. 2007, 71, 1298–1311. [Google Scholar] [CrossRef]
- Watarai, Y.; Ishizawa, M.; Ikura, T.; Zacconi, F.C.; Uno, S.; Ito, N.; Mourino, A.; Tokiwa, H.; Makishima, M.; Yamada, S. Synthesis, biological activities, and X-ray crystal structural analysis of 25-hydroxy-25(or 26)-adamantyl-17-[20(22),23-diynyl]-21-norvitamin D compounds. J. Med. Chem. 2015, 58, 9510–9521. [Google Scholar] [CrossRef]
- Yang, D.; Anderson, P.H.; Wijenayaka, A.R.; Barratt, K.R.; Triliana, R.; Stapledon, C.J.M.; Zhou, H.; Findlay, D.M.; Morris, H.A.; Atkins, G.J. Both ligand and vdr expression levels critically determine the effect of 1α,25-dihydroxyvitamin-D3 on osteoblast differentiation. J. Steroid Biochem. Mol. Biol. 2018, 177, 83–90. [Google Scholar] [CrossRef]
- Meyer, M.B.; Zella, L.A.; Nerenz, R.D.; Pike, J.W. Characterizing early events associated with the activation of target genes by 1,25-dihydroxyvitamin D3 in mouse kidney and intestine in vivo. J. Biol. Chem. 2007, 282, 22344–22352. [Google Scholar] [CrossRef]
- Egbuna, O.; Quinn, S.; Kantham, L.; Butters, R.; Pang, J.; Pollak, M.; Goltzman, D.; Brown, E. The full-length calcium-sensing receptor dampens the calcemic response to 1a,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. Am. J. Physiol. Ren. Physiol. 2009, 297, F720–F728. [Google Scholar] [CrossRef]
- Nguyen-Yamamoto, L.; Bolivar, I.; Strugnell, S.A.; Goltzman, D. Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis. J. Am. Soc. Nephrol. 2010, 21, 1713–1723. [Google Scholar] [CrossRef]
- Hourai, S.; Fujishima, T.; Kittaka, A.; Suhara, Y.; Takayama, H.; Rochel, N.; Moras, D. Probing a water channel near the a-ring of receptor-bound 1α,25-dihydroxyvitamin D3 with selected 2 alpha-substituted analogues. J. Med. Chem. 2006, 49, 5199–5205. [Google Scholar] [CrossRef]
- Tanimoto, K.; Matsumoto, T.; Nagaoka, Y.; Kazama, T.; Yamamoto, C.; Kano, K.; Nagaoka, M.; Saito, S.; Tokuhashi, Y.; Nakanishi, K. Phenotypic and functional properties of dedifferentiated fat cells derived from infrapatellar fat pad. Regen. Ther. 2022, 19, 35–46. [Google Scholar] [CrossRef]
- Okita, N.; Honda, Y.; Kishimoto, N.; Liao, W.; Azumi, E.; Hashimoto, Y.; Matsumoto, N. Supplementation of strontium to a chondrogenic medium promotes chondrogenic differentiation of human dedifferentiated fat cells. Tissue Eng. Part A 2015, 21, 1695–1704. [Google Scholar] [CrossRef]
- Kazama, T.; Fujie, M.; Endo, T.; Kano, K. Mature adipocyte-derived dedifferentiated fat cells can transdifferentiate into skeletal myocytes in vitro. Biochem. Biophys. Res. Commun. 2008, 377, 780–785. [Google Scholar] [CrossRef]
- Sakuma, T.; Matsumoto, T.; Kano, K.; Fukuda, N.; Obinata, D.; Yamaguchi, K.; Yoshida, T.; Takahashi, S.; Mugishima, H. Mature, adipocyte derived, dedifferentiated fat cells can differentiate into smooth muscle-like cells and contribute to bladder tissue regeneration. J. Urol. 2009, 182, 355–365. [Google Scholar] [CrossRef]
- Jumabay, M.; Zhang, R.; Yao, Y.; Goldhaber, J.I.; Bostrom, K.I. Spontaneously beating cardiomyocytes derived from white mature adipocytes. Cardiovasc. Res. 2010, 85, 17–27. [Google Scholar] [CrossRef]
- Jumabay, M.; Abdmaulen, R.; Urs, S.; Heydarkhan-Hagvall, S.; Chazenbalk, G.D.; Jordan, M.C.; Roos, K.P.; Yao, Y.; Bostrom, K.I. Endothelial differentiation in multipotent cells derived from mouse and human white mature adipocytes. J. Mol. Cell. Cardiol. 2012, 53, 790–800. [Google Scholar] [CrossRef]
- Kishimoto, N.; Momota, Y.; Hashimoto, Y.; Tatsumi, S.; Ando, K.; Omasa, T.; Kotani, J. The osteoblastic differentiation ability of human dedifferentiated fat cells is higher than that of adipose stem cells from the buccal fat pad. Clin. Oral Investig. 2014, 18, 1893–1901. [Google Scholar] [CrossRef]
- Kishimoto, N.; Honda, Y.; Momota, Y.; Tran, S.D. Dedifferentiated fat (DFAT) cells: A cell source for oral and maxillofacial tissue engineering. Oral Dis. 2018, 24, 1161–1167. [Google Scholar] [CrossRef]
Surface Marker | Positive Rate (%) |
---|---|
CD105 | 85.5 |
CD90 | 98.1 |
CD73 | 99.6 |
CD31 | 0.01 |
CD45 | 0.05 |
HLA-DR | 0.10 |
Species | Gene Symbol | Gene Name | Sequence |
---|---|---|---|
Human | BGLAP | bone gamma-carboxyglutamate protein | 5′-CCA GGC GCT ACC TGT ATC AA-3′ 5′-AAG CCG ATG TGG TCA GCC AA-3′ |
CYP24A1 | cytochrome P450 family 24 subfamily A member 1 | 5′-TGA ACG TTG GCT TCA GGA GAA-3′ 5′-AGG GTG CCT GAG TGT AGC ATC T-3′ | |
PPARG | peroxisome proliferator activated receptor gamma | 5′-CGT GGA TCT CTC CGT AAT GGA-3′ 5′-AAT AAG GTG GAG ATG CAG GCT C-3′ | |
RNA18SN4 | 18S rRNA | 5′-GTA ACC CGT TGA ACC CCA TT-3’ 5′-CCA TCC AAT CGG TAG TAG CG-3′ | |
RUNX2 | RUNX family transcription factor 2 | 5′-CAT TTG CAC TGG GTC ACA CGT A-3′ 5′-GAA TCT GGC CAT GTT TGT GCT C-3′ | |
SPP1 | secreted phosphoprotein 1 | 5′-ACT CCA ATC GTC CCT ACA GT-3′ 5′-TAG ACT CAC CGC TCT TCA TG-3′ | |
Mouse | Cyp24a1 | cytochrome P450 family 24 subfamily A member 1 | 5′-TGG AGA CGA CCG CAA ACA G-3′ 5′-AGG CAG CAC GCT CTG GAT T-3′ |
Gapdh | glyceraldehyde-3-phosphate dehydrogenase | 5′-TGC ACC ACC AAC TGC TTA G-3′ 5′-GAT GCA GGG ATG ATG TTC-3′ |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ishizawa, M.; Takano, M.; Kittaka, A.; Matsumoto, T.; Makishima, M. 2α-Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast Differentiation of Dedifferentiated Fat Cells. Biomolecules 2024, 14, 706. https://doi.org/10.3390/biom14060706
Ishizawa M, Takano M, Kittaka A, Matsumoto T, Makishima M. 2α-Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast Differentiation of Dedifferentiated Fat Cells. Biomolecules. 2024; 14(6):706. https://doi.org/10.3390/biom14060706
Chicago/Turabian StyleIshizawa, Michiyasu, Masashi Takano, Atsushi Kittaka, Taro Matsumoto, and Makoto Makishima. 2024. "2α-Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast Differentiation of Dedifferentiated Fat Cells" Biomolecules 14, no. 6: 706. https://doi.org/10.3390/biom14060706